C88.3
Immunoproliferative small intestinal disease
Clinical Classification Guidelines
Inclusion Terms
- Alpha heavy chain disease
- Mediterranean lymphoma
Medical Intelligence & Overview
Immunoproliferative Small Intestinal Disease, classified under ICD-10 code C88.3, is a rare type of disorder characterized by abnormal growth of immune cells in the small intestine. This condition is often associated with the production of abnormal immunoglobulin components, particularly alpha heavy chains, and is also known as Alpha Heavy Chain Disease or Mediterranean Lymphoma. It primarily affects individuals in certain geographic regions, notably around the Mediterranean basin, and presents with a range of gastrointestinal symptoms due to the proliferation of abnormal lymphoid tissue.
Causes & Symptoms
Clinical Causes: Chronic infections, particularly with Helicobacter pylori or other bacteria endemic to certain regions. Genetic predisposition or familial tendencies affecting immune regulation. Environmental factors such as exposure to specific pathogens or carcinogens. Immune system dysregulation leading to abnormal B-cell proliferation. Association with other lymphoid neoplasms in some cases.
Key Symptoms: Chronic diarrhea which may be persistent or intermittent. Abdominal pain or discomfort, often related to swelling or thickening of intestinal walls. Weight loss due to malabsorption or decreased nutritional intake. Nutritional deficiencies, including anemia, due to impaired absorption. Palpable abdominal mass in advanced cases. Fever or night sweats in some patients, indicating systemic involvement. General fatigue and weakness.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Immunoproliferative Small Intestinal Disease typically involves a combination of clinical assessment and diagnostic tests: - **Endoscopic Examination**: Visual inspection via biopsy to observe intestinal mucosa changes. - **Histopathology**: Microscopic examination of tissue samples to identify abnormal lymphoid proliferations and detect characteristic alpha heavy chain production. - **Immunohistochemistry**: Testing for specific immunoglobulin chains to confirm alpha heavy chain disease. - **Imaging Studies**: Techniques such as CT scans or MRI to evaluate the extent of intestinal involvement and rule out other causes. - **Laboratory Tests**: Blood tests measuring blood counts, nutritional status, and specific immunoglobulin levels. - **Bacterial and Viral Tests**: Screening for infectious agents that may be linked to disease development.
Treatment Protocols: Management of Immunoproliferative Small Intestinal Disease often involves tailored approaches based on disease severity and progression: - **Antibiotics**: To eradicate underlying infections such as Helicobacter pylori if present. - **Chemotherapy and Immunotherapy**: Using agents to target abnormal lymphoid cells, especially in cases progressing towards lymphoma. - **Surgical Intervention**: In cases of significant intestinal obstruction, perforation, or localized tumors. - **Supportive Care**: Nutritional support, including dietary modifications and supplementation, to address malabsorption and deficiencies. - **Regular Monitoring**: Ongoing assessment to detect potential progression to more aggressive lymphomas or complications. - **Emerging Therapies**: Clinical trials exploring targeted therapies aimed at the molecular pathways involved in disease proliferation.
Clinical Advice & FAQs
Billing Guidance
Is C88.3 a billable ICD-10 code?
Yes, C88.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C88.3?
Clinical documentation must specify the nature of Immunoproliferative small intestinal disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference